Vibose 300 mcg (Tablet)

Indications

• Reduction in Post-Prandial Hyperglycaemia
• Non-insulin-dependent diabetes mellitus (NIDDM) treatment
• Combination therapy with other Oral Hypoglycaemic Agents (OHAs)
• In elderly patients and those with hepatic dysfunction or renal impairments
• Prevention of onset of type 2 diabetes mellitus in impaired glucose tolerance
• Treatment of glycogen storage disease
• Treatment of non-diabetic Hyperinsulinemia
• Prevention of hypoglycaemic attacks in steroid induced diabetes mellitus

Description

• Selective inhibition of α-glucosidase in the enteric canal
• Delays digestion and absorption of carbohydrate
• Suppression of sharp increase in post-prandial plasma glucose

Pharmacology

• Competitive inhibitors of alpha-glucosidase enzymes
• Inhibition of membrane-bound intestinal alpha-glucosidases
• Inhibition of pancreatic alpha-amylase
• Reduction in the rate of digestion of complex carbohydrates

Dosage & Administration

• Orally administered in a single dose of 0.2 mg, 3 times a day
• Pediatrics: Safety and effectiveness not established
• Geriatrics: Desirable to start at a lower dose

Interaction

• Should be administered with care when co-administered with antidiabetic drugs
• Drugs enhancing the hypoglycaemic action
• Drugs diminishing the hypoglycaemic action

Contraindications

• Hypersensitivity to Voglibose or excipients
• Diabetic ketoacidosis or pre-coma
• Severe infection, operation, or serious trauma
• Gastrointestinal obstruction or predisposition to it

Side Effects

• Diarrhoea, loose stools, abdominal pain
• Constipation, loss of appetite, nausea, vomiting, heartburn
• Increased gas, intestinal obstruction-like symptoms
• Hypoglycaemia with OHAs plus Vibose
• Delay in digestion and absorption of disaccharides
• Fulminant hepatitis, serious liver dysfunction, jaundice
• Numbness, edema, blurred vision, malaise, weakness
• Hyperkalemia, increased pancreatic enzyme (serum amylase)

Pregnancy & Lactation

• Safety in pregnancy not established
• Recommended to avoid administration in lactating and nursing mothers

Precautions & Warnings

• Careful administration in patients receiving other antidiabetic drugs
• Caution in patients with a history of laparotomy or ileus
• Special attention in patients with chronic intestinal disease
• Close observation in patients with serious hepatic or renal dysfunction
• Elderly patients need careful administration

Use in Special Populations

• Poorly absorbed after oral doses with negligible renal excretion

Overdose Effects

• Transient increase in flatulence, diarrhoea, and abdominal discomfort
• No serious systemic reactions expected in the event of an overdose

Therapeutic Class

• Alpha-Glucosidase inhibitor

Storage Conditions

• Cool and dry place
• Keep out of the reach of children
• Protect from light

Related Brands

• Vibose 200 mcg (Tablet) - beximco-pharmaceuticals-ltd